The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy.
about
Blockade of PD-1 Signaling Enhances Th2 Cell Responses and Aggravates Liver Immunopathology in Mice with Schistosomiasis japonica.Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid.Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 DecoySalvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.The immune system and cancer evasion strategies: therapeutic concepts.PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.Ocular toxicities of MEK inhibitors and other targeted therapies.Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.Characterization of the tumor microenvironment in primary cutaneous CD30-positive lymphoproliferative disorders: a predominance of CD163-positive M2 macrophages.Inhibitors of the PD-1/PD-L1 Pathway Can Mobilize the Immune System: An Innovative Potential Therapy for Cancer and Chronic Infections.Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior.Ex-vivo assessment of drug response on breast cancer primary tissue with preserved microenvironments.Distinct Immunoregulatory Mechanisms in Mesenchymal Stem Cells: Role of the Cytokine Environment.Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases.Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells.Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.Increased CCR7PD-1CXCR5CD4 T Cells in Peripheral Blood Mononuclear Cells Are Correlated with Immune Activation in Patients with Chronic HBV InfectionExpression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma
P2860
Q36177129-4D989873-00CA-49E4-8EFC-2D239B2344ADQ36853857-45B6706B-F78C-4562-8D46-264AA5C23283Q36859353-4235EA79-E415-40B4-93F3-DBA5966B3A53Q38664909-43D5048B-4A53-434F-9120-D68F0A066BFDQ38691172-FF29BF54-391F-4AF9-B549-E6EA2CBAF508Q38751460-8FAC4C7F-93EE-4620-B032-59F7FA1BD895Q38764273-8B8462C5-D74D-40F0-B2E2-5A7426F4DBC5Q39045550-63BFB7FA-AD00-4C3B-9248-24F68B28051DQ39402079-E30F575A-BC49-48E9-93D6-998761A16929Q40713654-69C14C12-5629-41AA-8F7E-6F7E9745427EQ40753120-6F365D81-E573-41CD-AA7F-5325D5292E48Q47181092-8319F1D3-7A52-4904-B681-A1D278849BD6Q47791066-216B3BA5-837C-47C8-B3B3-05661DBDE9C4Q48336724-F781C526-87FD-40EA-9247-B2D7427D4CF8Q51099991-8407D2B2-58F6-4F5C-BF0B-AE00951E0223Q52643503-7C5B5679-469F-4A8E-9BF6-9F0345DC2C1CQ55174561-2CA8BA22-D59A-4F32-9AFB-24A4798DE459Q58580123-3C13A1F4-D276-4F1E-9931-B183A5E82B59Q58691451-1BF6F0C1-F983-4189-89E9-1D67BDDCD3D1
P2860
The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The PD-1/PD-L1 pathway: biolog ...... tment target in immunotherapy.
@en
type
label
The PD-1/PD-L1 pathway: biolog ...... tment target in immunotherapy.
@en
prefLabel
The PD-1/PD-L1 pathway: biolog ...... tment target in immunotherapy.
@en
P2860
P50
P1476
The PD-1/PD-L1 pathway: biolog ...... tment target in immunotherapy.
@en
P2093
Sylvia Hoeller
P2860
P304
P356
10.1517/14728222.2014.980235
P407
P577
2014-12-10T00:00:00Z